Moreover, as the clinical failure of immune checkpoint inhibitors for cancer treatment has been linked to overactive TGFβ signaling activity (at least under some circumstances), we are witnessing a profound renewed interest in TGFβ as a target for cancer therapy. Here, TGFB1 is linked to cancer.